Human Reproduction, Vol. 17, No. 6, 1472-1476,
June 2002
© 2002 European Society of Human Reproduction and Embryology
Pharmacokinetic study of different dosing regimens of levonorgestrel for emergency contraception in healthy women
1 Center for Biomedical Research, The Population Council, New York, NY, USA, 2 PROFAMILIA, Santo Domingo, Dominican Republic, 3 CEMICAMP, Campinas, SP, Brasil, 4 Steroid Research Laboratory, Institute of Biomedicine, University of Helsinki, Helsinki, Finland and 5 Pharsight Corporation, Cary, NC, USA
BACKGROUND: Levonorgestrel (LNG) is a commonly used progestin for emergency contraception; however, little is known about its pharmacokinetics and optimal dose for use. METHODS: Serum levels of LNG and sex hormone-binding globulin (SHBG) were measured in five women who received three different regimens: A: 0.75 mg LNG twice with a 12 h interval; B: 0.75 mg twice with a 24 h interval; and C: 1.50 mg in a single dose, with a washout period of 28 days between each treatment. Blood samples were taken before pill intake and at 1, 2, 4, 8 and 12 h after each dose, every 12 h up to day 4 and every 24 h until day 10. LNG and SHBG were measured in all samples. RESULTS: Maximum LNG concentrations were of ~27 nmol/l for treatments A and B, and close to 40 nmol/l for treatment C. The area under the curve was significantly higher for treatment C during the first 12 h, and significantly lower for treatment B during the first 24 h. After 48 h and up to 9 days from onset of treatment, serum LNG levels were similar in all three regimens. SHBG levels remained stable for 24 h, decreasing to 60% of the initial value from day 5 until day 10, with no difference between regimens. CONCLUSIONS: The similarity of LNG serum levels obtained with one single dose of 1.5 mg or two doses of 0.75 mg with a 12 h interval justify a clinical comparison of these two regimes.
Key words: emergency contraception/levonorgestrel/pharmacokinetics/SHBG
6 To whom correspondence should be addressed at: PROFAMILIA, Biomedical Research Department, P.O. Box 1053, Santo Domingo, Dominican Republic. E-mail: biomedica{at}codetel.net.do
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Gainer, R. Massai, S. Lillo, V. Reyes, M.L. Forcelledo, R. Caviedes, C. Villarroel, and J. Bouyer Levonorgestrel pharmacokinetics in plasma and milk of lactating women who take 1.5 mg for emergency contraception Hum. Reprod., June 1, 2007; 22(6): 1578 - 1584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wai Ngai, S. Fan, S. Li, L. Cheng, J. Ding, X. Jing, E. H. Yu Ng, and P. Chung Ho A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraception Hum. Reprod., January 1, 2005; 20(1): 307 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hamoda, P. W. Ashok, C. Stalder, G. M. M. Flett, E. Kennedy, and A. Templeton A Randomized Trial of Mifepristone (10 mg) and Levonorgestrel for Emergency Contraception Obstet. Gynecol., December 1, 2004; 104(6): 1307 - 1313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.E. Ortiz, R.E. Ortiz, M.A. Fuentes, V.H. Parraguez, and H.B. Croxatto Post-coital administration of levonorgestrel does not interfere with post-fertilization events in the new-world monkey Cebus apella Hum. Reprod., June 1, 2004; 19(6): 1352 - 1356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Haimov-Kochman, H. Amsalem, A. Adoni, Y. Lavy, and I. M. Spitz Management of a perforated levonorgestrel-medicated intrauterine device--a pharmacokinetic study: Case report Hum. Reprod., June 1, 2003; 18(6): 1231 - 1233. [Abstract] [Full Text] [PDF]
|
|